# BLK

## Overview
The BLK gene encodes the BLK proto-oncogene, a member of the Src family of non-receptor tyrosine kinases, which are integral to various cellular signaling pathways. This protein is predominantly expressed in B cells, where it plays a pivotal role in B cell receptor signaling, crucial for B cell development, differentiation, and activation (Gocek2014Nonreceptor). The BLK protein contains several functional domains, including SH2 and SH3 domains, which facilitate protein-protein interactions and regulate its kinase activity (Superti‐Furga1995Structure‐function). Through its kinase activity, BLK is involved in phosphorylation processes that influence cell growth and immune responses, underscoring its importance in maintaining normal immune function (Roskoski2015Src). Dysregulation of BLK activity has been associated with various diseases, including autoimmune disorders and certain cancers, highlighting its clinical significance (Taher2017Intracellular).

## Structure
The BLK gene encodes a protein that is part of the Src family of tyrosine kinases, which are involved in various cellular processes. The molecular structure of BLK includes several key domains: a unique N-terminal region, an SH3 domain, an SH2 domain, and a kinase domain (SH1) (Ingley2008Src). The SH3 domain interacts with proline-rich motifs, while the SH2 domain binds phosphotyrosine motifs, both of which are crucial for protein-protein interactions (Superti‐Furga1995Structure‐function). The kinase domain is responsible for the enzymatic activity of BLK (Ingley2008Src).

Post-translational modifications of BLK include myristoylation, which is necessary for palmitoylation, aiding in membrane association and regulation (Superti‐Furga1995Structure‐function). Phosphorylation plays a significant role in regulating BLK activity, with a conserved tyrosine residue in the C-terminal tail being phosphorylated by Csk, leading to negative regulation (Superti‐Furga1995Structure‐function). The SH3 and SH2 domains help maintain the inactive state through intramolecular interactions (Ingley2008Src).

BLK, like other Src family kinases, may have alternative splice variants, which can result in different isoforms, potentially affecting its function and regulation.

## Function
BLK (B lymphoid tyrosine kinase) is a member of the Src family of non-receptor tyrosine kinases, primarily expressed in B cells. It plays a crucial role in B cell receptor signaling, which is essential for B cell development, differentiation, and activation. BLK is involved in phosphorylation processes that regulate various cellular functions, including cell growth and immune responses (Gocek2014Nonreceptor).

BLK, like other Src family kinases, contains SH2 and SH3 domains that are involved in docking to phosphorylated tyrosine residues, which regulate its kinase activity. These domains facilitate interactions with other proteins, influencing cellular signaling pathways (Gocek2014Nonreceptor). The kinase activity of BLK is tightly regulated through phosphorylation and dephosphorylation at specific tyrosine residues, similar to other Src family kinases (Roskoski2015Src).

In healthy human cells, BLK's activity is crucial for the proper functioning of the immune system, particularly in the signaling pathways that govern B cell responses. Its role in these pathways ensures that B cells can effectively respond to antigens, contributing to the adaptive immune response (Gocek2014Nonreceptor). The precise regulation of BLK activity is essential for maintaining normal immune function and preventing aberrant signaling that could lead to disease.

## Clinical Significance
Mutations and alterations in the BLK gene have been implicated in several diseases, particularly autoimmune disorders. A specific mutation in the BLK gene, where proline replaces leucine at position 3 (L3P-BLK), has been identified in patients with Common Variable Immunodeficiency (CVID). This mutation results in a loss-of-function that affects the Src and Syk signaling pathways, leading to reduced B cell activation and impaired antigen presentation to T helper cells. Patients with this mutation exhibit low levels of IgG and IgA, normal IgM levels, poor response to vaccinations, and recurrent pulmonary infections (Griffin2020B).

BLK is also associated with autoimmune diseases such as systemic lupus erythematosus (SLE), Sjögren's syndrome, rheumatoid arthritis, systemic sclerosis, and primary antiphospholipid syndrome. Variants in BLK may affect B-cell receptor signaling, contributing to these conditions (Taher2017Intracellular). Polymorphisms in BLK have been identified as risk factors for SLE susceptibility, indicating its role in the pathogenesis of autoimmune diseases (Taher2017Intracellular). Additionally, deletions in the BLK gene have been detected in a subset of pediatric Burkitt lymphoma cases, suggesting a potential role in the disease, although the clinical implications are not fully detailed (Burkhardt2022Clinical).

## Interactions
The BLK gene encodes a non-receptor tyrosine kinase that is part of the Src family and plays a significant role in B-cell receptor signaling. BLK is involved in the phosphorylation of FAM83A, a protein that interacts with the Wnt/β-catenin signaling pathway, which is crucial in pancreatic tumorigenesis. BLK phosphorylates FAM83A at the tyrosine 138 residue, enhancing its interaction with β-catenin and promoting oncogenic Wnt/β-catenin-mediated transcription (Zhou2023Blymphoid). This phosphorylation inhibits the assembly of the β-catenin destruction complex, preventing β-catenin degradation and leading to its accumulation and nuclear translocation, where it activates transcription of oncogenic target genes (Zhou2023Blymphoid).

BLK's interaction with FAM83A is critical for stabilizing β-catenin by inhibiting the binding of GSK3β and AXIN1 to β-catenin, thus promoting its nuclear translocation and transcriptional activity (Zhou2023Blymphoid). The phosphorylation of FAM83A by BLK is a key mechanism linking Wnt/β-catenin signaling to pancreatic cancer progression, highlighting the potential of targeting this interaction for therapeutic purposes (Zhou2023Blymphoid). BLK's role in these interactions underscores its importance in modulating signaling pathways involved in cancer development.


## References


[1. (Ingley2008Src) Evan Ingley. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1784(1):56–65, January 2008. URL: http://dx.doi.org/10.1016/j.bbapap.2007.08.012, doi:10.1016/j.bbapap.2007.08.012. This article has 246 citations.](https://doi.org/10.1016/j.bbapap.2007.08.012)

[2. (Burkhardt2022Clinical) Birgit Burkhardt, Ulf Michgehl, Jonas Rohde, Tabea Erdmann, Philipp Berning, Katrin Reutter, Marius Rohde, Arndt Borkhardt, Thomas Burmeister, Sandeep Dave, Alexandar Tzankov, Martin Dugas, Sarah Sandmann, Falko Fend, Jasmin Finger, Stephanie Mueller, Nicola Gökbuget, Torsten Haferlach, Wolfgang Kern, Wolfgang Hartmann, Wolfram Klapper, Ilske Oschlies, Julia Richter, Udo Kontny, Mathias Lutz, Britta Maecker-Kolhoff, German Ott, Andreas Rosenwald, Reiner Siebert, Arend von Stackelberg, Brigitte Strahm, Wilhelm Woessmann, Martin Zimmermann, Myroslav Zapukhlyak, Michael Grau, and Georg Lenz. Clinical relevance of molecular characteristics in burkitt lymphoma differs according to age. Nature Communications, July 2022. URL: http://dx.doi.org/10.1038/s41467-022-31355-8, doi:10.1038/s41467-022-31355-8. This article has 26 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-022-31355-8)

[3. (Gocek2014Nonreceptor) Elzbieta Gocek, Anargyros N. Moulas, and George P. Studzinski. Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells. Critical Reviews in Clinical Laboratory Sciences, 51(3):125–137, January 2014. URL: http://dx.doi.org/10.3109/10408363.2013.874403, doi:10.3109/10408363.2013.874403. This article has 80 citations and is from a peer-reviewed journal.](https://doi.org/10.3109/10408363.2013.874403)

[4. (Roskoski2015Src) Robert Roskoski. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacological Research, 94:9–25, April 2015. URL: http://dx.doi.org/10.1016/j.phrs.2015.01.003, doi:10.1016/j.phrs.2015.01.003. This article has 564 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.phrs.2015.01.003)

[5. (Zhou2023Blymphoid) Cefan Zhou, Xiaoting Zhu, Nanxi Liu, Xueying Dong, Xuewen Zhang, Huili Huang, Yu Tang, Shicheng Liu, Mengyu Hu, Ming Wang, Xiaoling Deng, Shi Li, Rui Zhang, Yuan Huang, Hao Lyu, Shuai Xiao, Sang Luo, Declan William Ali, Marek Michalak, Xing-Zhen Chen, Zhentian Wang, and Jingfeng Tang. B-lymphoid tyrosine kinase-mediated fam83a phosphorylation elevates pancreatic tumorigenesis through interacting with β-catenin. Signal Transduction and Targeted Therapy, February 2023. URL: http://dx.doi.org/10.1038/s41392-022-01268-5, doi:10.1038/s41392-022-01268-5. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41392-022-01268-5)

[6. (Superti‐Furga1995Structure‐function) Giulio Superti‐Furga and Sara A. Courtneidge. Structure‐function relationships in src family and related protein tyrosine kinases. BioEssays, 17(4):321–330, April 1995. URL: http://dx.doi.org/10.1002/bies.950170408, doi:10.1002/bies.950170408. This article has 272 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/bies.950170408)

[7. (Griffin2020B) Dixie D. Griffin and William K. Dolen. B cell disorders in children: part ii. Current Allergy and Asthma Reports, August 2020. URL: http://dx.doi.org/10.1007/s11882-020-00963-z, doi:10.1007/s11882-020-00963-z. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11882-020-00963-z)

[8. (Taher2017Intracellular) Taher E. Taher, Jonas Bystrom, Voon H. Ong, David A. Isenberg, Yves Renaudineau, David J. Abraham, and Rizgar A. Mageed. Intracellular b lymphocyte signalling and the regulation of humoral immunity and autoimmunity. Clinical Reviews in Allergy &amp; Immunology, 53(2):237–264, April 2017. URL: http://dx.doi.org/10.1007/s12016-017-8609-4, doi:10.1007/s12016-017-8609-4. This article has 37 citations.](https://doi.org/10.1007/s12016-017-8609-4)